WithdrawnPhase 4

Efficacy of Topical Apraclonidine for the Treatment of Ocular Synkinesis

Stopped: The project never opened.

0Started 2025-12

Plain-language summary

The purpose of this study is to determine efficacy of apraclonidine for patients with ocular synkinesis, who are seen in the UAB Facial Nerve Clinic.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18 years or older * Ability to speak and comprehend English * Ability to consent for themselves * Diagnosis of synkinesis affecting eye movement Exclusion Criteria: * Age less than 18 years * Unable to speak and comprehend English * Unable to consent for themselves * Diagnosis of congenital ptosis, Horner syndrome, myasthenia travis, mechanical ptosis * Visual field loss from causes unrelated to facial nerve injury * Currently receiving monoamine oxidase inhibitors * Known hypersensitivity to apraclonidine or other components of the drug under study

What they're measuring

Improvement in synkinesis symptoms

Timeframe: Baseline - 20 minutes after study drug administration

Trial details

NCT IDNCT05167760

SponsorUniversity of Alabama at Birmingham

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-11

View on ClinicalTrials.gov More Synkinesis trials